After seeing positive results for BG-12 (dimethyl fumarate) from several clinical trials involving people with relapsing-remitting MS, Biogen Idec submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for approval to market their new oral MS disease-modifying therapy.
Get the BG-12 facts
No comments:
Post a Comment